Cargando…

Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection

BACKGROUND: Hepatitis C virus (HCV) infection is a public health issue for which an effective universal screening method is urgently needed. An oral anti-HCV test could provide a noninvasive and rapid screening strategy for HCV infection. This study evaluated the performance of a new point-of-care o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lili, Zhang, Mingyuan, Hang, Lei, Kong, Fei, Yan, Hongqing, Zhang, Yumei, Feng, Xiangwei, Gao, Yuanda, Wang, Chang, Ma, Heming, Liu, Xu, Zhan, Mengru, Pan, Yu, Xu, Hongqin, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995050/
https://www.ncbi.nlm.nih.gov/pubmed/32005264
http://dx.doi.org/10.1186/s12985-020-1293-7
_version_ 1783493304194695168
author Liu, Lili
Zhang, Mingyuan
Hang, Lei
Kong, Fei
Yan, Hongqing
Zhang, Yumei
Feng, Xiangwei
Gao, Yuanda
Wang, Chang
Ma, Heming
Liu, Xu
Zhan, Mengru
Pan, Yu
Xu, Hongqin
Niu, Junqi
author_facet Liu, Lili
Zhang, Mingyuan
Hang, Lei
Kong, Fei
Yan, Hongqing
Zhang, Yumei
Feng, Xiangwei
Gao, Yuanda
Wang, Chang
Ma, Heming
Liu, Xu
Zhan, Mengru
Pan, Yu
Xu, Hongqin
Niu, Junqi
author_sort Liu, Lili
collection PubMed
description BACKGROUND: Hepatitis C virus (HCV) infection is a public health issue for which an effective universal screening method is urgently needed. An oral anti-HCV test could provide a noninvasive and rapid screening strategy for HCV infection. This study evaluated the performance of a new point-of-care oral assay developed by Well for the detection of HCV antibody. METHODS: Individuals from three centers with and without HCV infection were enrolled. All participants were tested for oral HCV antibody using the Well assay and for serum HCV antibody using established tests (ARCHITECT i2000 anti-HCV assay and InTec serum anti-HCV assay). For participants who obtained positive results, HCV RNA was tested for verification. Some patients underwent the OraQuick HCV test at the same time, and some self-tested with the Well assay during the same period. RESULTS: A total of 1179 participants, including 486 patients with chronic HCV infection, 108 patients with other liver diseases, and 585 individuals who underwent physical examination, were enrolled. The Well anti-HCV test had a sensitivity of 91.88% (95% confidence interval [CI]: 88.97–94.09%) and a specificity of 98.00% (96.58–98.86%) for oral HCV antibody detection. The consistency between the Well and InTec assays was 97.02% (1138/1179). The consistency between the Well and OraQuick assays was 98.50% (197/200). Furthermore, the results of self-testing were highly consistent with those of researcher-administered tests (Kappa = 0.979). In addition, the HCV RNA results also showed that HCV RNA could only be detected on 1 of the 39 false-negative samples, and for 172 positive HCV RNA results, 171 could be detected by the Well oral anti-HCV assay. CONCLUSIONS: The Well oral anti-HCV test offers high sensitivity and specificity and performed comparably to both the OraQuick assay and InTec assay for HCV diagnosis. Thus, the Well test represents a new tool for universal HCV screening to identify infected patients, particularly in regions with limited medical resources.
format Online
Article
Text
id pubmed-6995050
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69950502020-02-04 Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection Liu, Lili Zhang, Mingyuan Hang, Lei Kong, Fei Yan, Hongqing Zhang, Yumei Feng, Xiangwei Gao, Yuanda Wang, Chang Ma, Heming Liu, Xu Zhan, Mengru Pan, Yu Xu, Hongqin Niu, Junqi Virol J Research BACKGROUND: Hepatitis C virus (HCV) infection is a public health issue for which an effective universal screening method is urgently needed. An oral anti-HCV test could provide a noninvasive and rapid screening strategy for HCV infection. This study evaluated the performance of a new point-of-care oral assay developed by Well for the detection of HCV antibody. METHODS: Individuals from three centers with and without HCV infection were enrolled. All participants were tested for oral HCV antibody using the Well assay and for serum HCV antibody using established tests (ARCHITECT i2000 anti-HCV assay and InTec serum anti-HCV assay). For participants who obtained positive results, HCV RNA was tested for verification. Some patients underwent the OraQuick HCV test at the same time, and some self-tested with the Well assay during the same period. RESULTS: A total of 1179 participants, including 486 patients with chronic HCV infection, 108 patients with other liver diseases, and 585 individuals who underwent physical examination, were enrolled. The Well anti-HCV test had a sensitivity of 91.88% (95% confidence interval [CI]: 88.97–94.09%) and a specificity of 98.00% (96.58–98.86%) for oral HCV antibody detection. The consistency between the Well and InTec assays was 97.02% (1138/1179). The consistency between the Well and OraQuick assays was 98.50% (197/200). Furthermore, the results of self-testing were highly consistent with those of researcher-administered tests (Kappa = 0.979). In addition, the HCV RNA results also showed that HCV RNA could only be detected on 1 of the 39 false-negative samples, and for 172 positive HCV RNA results, 171 could be detected by the Well oral anti-HCV assay. CONCLUSIONS: The Well oral anti-HCV test offers high sensitivity and specificity and performed comparably to both the OraQuick assay and InTec assay for HCV diagnosis. Thus, the Well test represents a new tool for universal HCV screening to identify infected patients, particularly in regions with limited medical resources. BioMed Central 2020-01-31 /pmc/articles/PMC6995050/ /pubmed/32005264 http://dx.doi.org/10.1186/s12985-020-1293-7 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Liu, Lili
Zhang, Mingyuan
Hang, Lei
Kong, Fei
Yan, Hongqing
Zhang, Yumei
Feng, Xiangwei
Gao, Yuanda
Wang, Chang
Ma, Heming
Liu, Xu
Zhan, Mengru
Pan, Yu
Xu, Hongqin
Niu, Junqi
Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
title Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
title_full Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
title_fullStr Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
title_full_unstemmed Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
title_short Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
title_sort evaluation of a new point-of-care oral anti-hcv test for screening of hepatitis c virus infection
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995050/
https://www.ncbi.nlm.nih.gov/pubmed/32005264
http://dx.doi.org/10.1186/s12985-020-1293-7
work_keys_str_mv AT liulili evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT zhangmingyuan evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT hanglei evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT kongfei evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT yanhongqing evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT zhangyumei evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT fengxiangwei evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT gaoyuanda evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT wangchang evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT maheming evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT liuxu evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT zhanmengru evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT panyu evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT xuhongqin evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection
AT niujunqi evaluationofanewpointofcareoralantihcvtestforscreeningofhepatitiscvirusinfection